Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
India trial finds limited effectiveness from convalescent plasma
Fri October 23rd - Using convalescent plasma to treat moderately ill COVID-19 patients did not reduce severity of the illness or risk of death, according to the findings of a small clinical trial published today. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
For books, child safety and gift ideas click here

Immune programming blood cancer hope

Monday December 9th, 2013

A radical new technique, based on reprogramming immune system cells, is proving a "powerful" treatment, researchers revealed yesterday.

Promising results from the first patients treated with the genetically engineered T-cells were revealed at the conference of the American Society of Hematology in New Orleans, USA.

Some 59 patients with chronic and acute lymphocytic leukaemia have received the treatment, starting in 2010, in some cases after conventional bone marrow transplant treatments failed.

Known as CTL019, it involves removing patient T cells and reprogramming them in laboratory conditions with a gene transfer technique based on a lentivirus.

The process is known as chimeric antigen cell receptor engineering and is part of an emerging field dubbed "precision medicine."

Out of three patients with chronic disease treated in 2010, two remain in remission after receiving the treatment, known as CTL019, researchers said.

The researchers say that out of 32 adult patients in total with chronic disease, seven have now experienced complete remission and another eight responded to therapy.

Out of 22 child patients with acute disease, 19 experienced complete remission and five have relapsed, including Emily Whitehead, aged eight. Meanwhile five adults with acute disease have all enjoyed complete remission, the researchers say.

Researcher Professor Carl June, of the University of Pennsylvania, said: "In a very short time, we've learned so much about how CTL019 works and how powerful it can be.

"Our findings show that the human immune system and these modified hunter cells are working together to attack tumours in an entirely new way."

Doctors at the Children's Hospital of Philadelphia, Pennsylvania, said Emily remained free of cancer after treatment last year and is now back at school.

Researcher Dr Stephan Grupp said: "Our results serve as another important milestone in demonstrating the potential of this cell therapy for patients who have no other therapeutic options.

"We are also very excited that this approach has worked and been safe in patients who have relapsed after a bone marrow transplant."

Tags: Cancer | Child Health | Genetics | North America

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)